AstraZeneca is distributing a viral vector-based COVID-19 vaccine product in Canada and other countries called ChAdOx1 nCoV-19. It is marketed in Canada as Vaxzevria.1)


AstraZeneca was a founding member of the Alliance for a Stronger FDA.2)

AstraZeneca is a member organization of the World Economic Forum.3)


AstraZeneca acquired Alexion in 2021, adding its rare disease brand to the company's portfolio.4)

Payments from AstraZeneca

The following is a developing list of individuals and organizations that AstraZeneca has given money to related to the COVID-19 pandemic:

Payments to Individuals

Name Type Amount Description
David Fisman Honorarium Unknown Honorarium paid for advisory board meetings regarding COVID-19 related projects.5)
Kyla Hildebrand Research Unknown Research funding for allergy study6)

Payments to Organizations

Name Type Amount Description
St. Michaels Hospital Foundation Donation $1,000,000.00 - $2,499,999.00 Lifetime donations.7)
University Hospitals Kingston Foundation Donation $50,000.00 – $99,999.00 Cumulative donations up to December 31, 2019.8)
Health Canada. (2021, November 23). AstraZeneca Vaxzevria COVID-19 vaccine. Government of Canada. Retrieved December 5, 2021, from
AstraZeneca Calls for FDA Funding Increase. (2010, September 20). Pharmaceutical Technology.
AstraZeneca. (2021, December 3). World Economic Forum.
Kemp, A. (2021, July 21). Acquisition of Alexion completed. AstraZeneca.
Fisman, D. (2021). Declaration of Interest. Ontario COVID-19 Science Advisory Table.
Chan, E. S., Abrams, E. M., Hildebrand, K. J., & Watson, W. (2018). Early introduction of foods to prevent food allergy. Allergy, Asthma & Clinical Immunology, 14(S2).
St. Michael’s Foundation 2020/21 Annual Report. (2021). FlippingBook.
Recognizing your contribution. University Hospitals Kingston Foundation. Retrieved February 21, 2022, from
Back to top